Treatment Options in Refractory Autoimmune Encephalitis Alessandro DinotoSergio FerrariSara Mariotto Current Opinion Open access 02 August 2022 Pages: 919 - 931
New Oral Drugs for Migraine Nazia KarsanPeter J. Goadsby Review Article Open access 29 August 2022 Pages: 933 - 949
Benzodiazepines in the Management of Seizures and Status Epilepticus: A Review of Routes of Delivery, Pharmacokinetics, Efficacy, and Tolerability Ricardo KienitzLara KayLaurent M. Willems Review Article Open access 16 August 2022 Pages: 951 - 975
Improvements in Cognitive Processing Speed, Disability, and Patient-Reported Outcomes in Patients with Early Relapsing-Remitting Multiple Sclerosis Treated with Natalizumab: Results of a 4-year, Real-World, Open-Label Study Jai PerumalRoumen BalabanovRobert J. Fox Original Research Article Open access 05 September 2022 Pages: 977 - 993
Onasemnogene Abeparvovec: A Review in Spinal Muscular Atrophy Hannah A. Blair Adis Drug Evaluation 12 August 2022 Pages: 995 - 1005
Sodium Phenylbutyrate and Ursodoxicoltaurine: First Approval Young-A Heo AdisInsight Report 30 July 2022 Pages: 1007 - 1013
Correction: A Guideline and Checklist for Initiating and Managing Clozapine Treatment in Patients with Treatment-Resistant Schizophrenia C. U. CorrellOfer AgidOliver D. Howes Correction Open access 17 August 2022 Pages: 1015 - 1015
Correction to: Antiseizure Drugs and Movement Disorders Michel Sáenz-FarretMarina A. J. TijssenAlfonso Fasano Correction 17 August 2022 Pages: 1017 - 1018